Aclaris Announces Pricing of Initial Public Offering

MALVERN, Pa.Oct. 6, 2015 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price to the public of $11.00 per share. The shares have been approved for listing on The NASDAQ Global Select Market and are expected to begin trading under the ticker symbol "ACRS" on October 7, 2015. All of the common stock is being offered by Aclaris. In addition, Aclaris has granted the underwriters a 30-day option to purchase up to 750,000 additional shares of common stock at the initial public offering price. The offering is expected to close on October 13, 2015, subject to customary closing conditions.

Jefferies LLC and Citigroup Global Markets Inc. are acting as joint book-running managers for the offering. William Blair & Company, L.L.C. is acting as a co-manager.

The offering will be made only by means of a prospectus. A copy of the final prospectus, when available, may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 547-6340 or by email at [email protected], or Citigroup Global Markets Inc., c/o Broadridge Financial Solutions1155 Long Island Avenue,Edgewood, New York 11717, by telephone at (800) 831-9146, or by email at [email protected].

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on October 6, 2015.

This press release does not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company focused on identifying, developing, and commercializing novel drugs to address unmet needs in dermatology. Aclaris Therapeutics, Inc. is based in Malvern, Pennsylvania.

CONTACT: Aclaris Contact
         Frank Ruffo
         Chief Financial Officer
         484-324-7933
         [email protected]

         Investor Contact
         Patricia L. Bank
         Westwicke Partners
         Managing Director
         415-513-1284
         [email protected]

         Media Contact
         Mike Beyer
         Sam Brown, Inc.
         312-961-2502
         [email protected]

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

NYC’s outstanding talent and funding, the city is rich with life science real estate offerings across the five boroughs.

Sutro Biopharma’s lead antibody-drug conjugate shrank tumors in 13% of patients with ovarian cancer who had tried a median of six other treatments.

Immuno-oncology biotech Silverback Therapeutics has more than doubled its original IPO hopes.